Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: A case report

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 3, 2002, Pages 183-185

  Begelman, Susan M ^a   Deitcher, Steven R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antithrombin; Heparin; Lepirudin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; LEPIRUDIN; RECOMBINANT PROTEIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AMBULATORY CARE; ARTICLE; CASE REPORT; EMBOLECTOMY; HEART TRANSPLANTATION; HUMAN; LUNG EMBOLISM; MALE; METHODOLOGY; POSTOPERATIVE COMPLICATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS; BLEEDING; BLEEDING TENDENCY; CARDIOGENIC SHOCK; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEART ASSIST DEVICE; HEART INFARCTION; LONG TERM CARE; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; POINT MUTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA VEIN; STOP CODON; STROKE; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AMBULATORY CARE; ANTICOAGULANTS; EMBOLECTOMY; HEART TRANSPLANTATION; HIRUDINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0036624458     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020435108773     Document Type: Article

References (10)

1. Deitcher SR, Olin JW, Bartholomew J. How to use low-molecular weight heparin for outpatient management of deep vein thrombosis. Cleveland Clinic Journal of Medicine 1999;66:329-331.
2. Deitcher SR, Carman TL. Heparin induced thrombocytopenia: natural history, diagnosis, and management. Vascular Medicine 2001;6:113-119.
3. Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb Hemost 1986;12:1-11.
4. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-185.
5. Tarantino MD, Curtis SM, Johnson GS, Waye JS, Blajchman MA. A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia. Am J Hematol 1999;60:126-129.
6. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23.
7. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
8. Schiele F, Vuillemenot A, Kramarz Ph, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:558-562.
9. Schiele F, Lindgaerde F, Eriksson H, et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre-prospective dose-ranging randomized trial. Thromb Haemost 1997;77:834-838.
10. Andreescu AC, Cushman M, Hammond JM, Wood ME. Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature). J Thromb Thrombolysis 2001;11:33-37.